Skip to main content
SpringerLink
Log in

Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review

  • Review
  • Published:
European Child & Adolescent Psychiatry Aims and scope Submit manuscript

Abstract

We performed an updated review of the available literature on weight gain and increase of body mass index (BMI) among children and adolescents treated with antipsychotic medications. A PubMed search was conducted specifying the following MeSH terms: (antipsychotic agents) hedged with (weight gain) or (body mass index). We selected 127 reports, including 71 intervention trials, 42 observational studies and 14 literature reviews. Second-generation antipsychotics (SGAs), in comparison with first-generation antipsychotics, are associated with a greater risk for antipsychotic-induced weight gain although this oversimplification should be clarified by distinguishing across different antipsychotic drugs. Among SGAs, olanzapine appears to cause the most significant weight gain, while ziprasidone seems to cause the least. Antipsychotic-induced BMI increase appears to remain regardless of the specific psychotropic co-treatment. Children and adolescents seem to be at a greater risk than adults for antipsychotic-induced weight gain; and the younger the child, the higher the risk. Genetic or environmental factors related to antipsychotic-induced weight gain among children and adolescents are mostly unknown, although certain genetic factors related to serotonin receptors or hormones such as leptin, adiponectin or melanocortin may be involved. Strategies to reduce this antipsychotic side effect include switching to another antipsychotic drug, lowering the dosage or initiating treatment with metformin or topiramate, as well as non-pharmacological interventions. Future research should avoid some methodological limitations such as not accounting for age- and sex-adjusted BMI (zBMI), small sample size, short period of treatment, great heterogeneity of diagnoses and confounding by indication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Almandil NB, Wong IC (2011) Review on the current use of antipsychotic drugs in children and adolescents. Arch Dis Child Educ Pract Ed 96:192–196

    Article  PubMed  Google Scholar 

  2. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Ghuman JK, Lindsay RL (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15:869–884

    Article  PubMed  Google Scholar 

  3. Aman MG, Binder C, Turgay A (2004) Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 14:243–254

    Article  PubMed  Google Scholar 

  4. Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombin I, Moreno D (2009) Olanzapine compared to quetiapine in adolescents with a first psychotic episode. Eur Child Adolesc Psychiatry 18:418–428

    Article  PubMed  Google Scholar 

  5. Arman S, Sadramely MR, Nadi M, Koleini N (2008) A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Med J 29:1130–1134

    PubMed  Google Scholar 

  6. Armenteros JL, Davies M (2006) Antipsychotics in early onset Schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 15:141–148

    Article  PubMed  Google Scholar 

  7. Armenteros JL, Lewis JE, Davalos M (2007) Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46:558–565

    Article  PubMed  Google Scholar 

  8. Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J (1997) Risperidone in adolescents with schizophrenia: an open pilot study. J Am Acad Child Adolesc Psychiatry 36:694–700

    Article  PubMed  CAS  Google Scholar 

  9. Arnold LE, Farmer C, Kraemer HC, Davies M, Witwer A, Chuang S, DiSilvestro R, McDougle CJ, McCracken J, Vitiello B, Aman MG, Scahill L, Posey DJ, Swiezy NB (2010) Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability. J Child Adolesc Psychopharmacol 20:83–93

    Article  PubMed  Google Scholar 

  10. Bachmann CJ, Gebhardt S, Lehr D, Haberhausen M, Kaiser C, Otto B, Theisen FM (2012) Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment. Z Kinder Jugendpsychiatr Psychother 40:151–158 (quiz 158–159)

    Article  PubMed  Google Scholar 

  11. Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M, Remschmidt H, Theisen FM (2008) Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 30:108–112

    Article  PubMed  CAS  Google Scholar 

  12. Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Hiemke C, Remschmidt H, Theisen FM (2008) Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 30:462–466

    Article  PubMed  CAS  Google Scholar 

  13. Biederman J, Mick E, Spencer T, Dougherty M, Aleardi M, Wozniak J (2007) A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder. Bipolar Disord 9:888–894

    Article  PubMed  CAS  Google Scholar 

  14. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J (2007) An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 12:683–689

    PubMed  Google Scholar 

  15. Björkhem-Bergman L, Asplund AB, Lindh JD (2011) Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol 25:299–305

    Article  PubMed  Google Scholar 

  16. Bozina N, Medved V, Kuzman MR, Sain I, Sertic J (2007) Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients. J Psychopharmacol 21:728–734

    Article  PubMed  CAS  Google Scholar 

  17. Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697–701

    Article  PubMed  CAS  Google Scholar 

  18. Buitelaar JK (2000) Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 10:19–26

    Article  PubMed  CAS  Google Scholar 

  19. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT (2001) A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62:239–248

    Article  PubMed  CAS  Google Scholar 

  20. Cabanac M, Duclaux R, Spector NH (1971) Sensory feedback in regulation of body weight: is there a ponderostat? Nature 229:125–127

    Article  PubMed  CAS  Google Scholar 

  21. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA (2009) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19:101–109

    Article  PubMed  Google Scholar 

  22. Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA (2009) Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet 19:320–327

    Article  PubMed  Google Scholar 

  23. Calarge CA, del Miller D (2011) Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacol 21:163–169

    Article  PubMed  CAS  Google Scholar 

  24. Canitano R (2005) Clinical experience with Topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Dev 27:228–232

    Article  PubMed  Google Scholar 

  25. Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I, Gonzalez-Pinto A, Graell M, Paya B, Moreno D, de la Serna E, Arango C (2008) Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach. J Child Adolesc Psychopharmacol 18:327–336

    Article  PubMed  Google Scholar 

  26. Citrome L, Vreeland B (2008) Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 120:18–33

    Article  PubMed  Google Scholar 

  27. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C (2012) Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol 32:309–316

    Article  PubMed  CAS  Google Scholar 

  28. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM (2010) Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 10:418–430

    Article  PubMed  CAS  Google Scholar 

  29. Correia FAG, Bodanese R, Silva TL, Alvares JP, Aman M, Rohde LA (2005) Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry 44:748–755

    Article  Google Scholar 

  30. Correll CU (2011) Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry 72:e01

    Article  PubMed  Google Scholar 

  31. Correll CU (2005) Metabolic side effects of second-generation antipsychotics in children and adolescents: a different story? J Clin Psychiatry 66:1331–1332

    Article  PubMed  Google Scholar 

  32. Correll CU (2007) Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 46:687–700

    Article  PubMed  Google Scholar 

  33. Correll CU, Carlson HE (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45:771–791

    Article  PubMed  Google Scholar 

  34. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302:1765–1773

    Article  PubMed  CAS  Google Scholar 

  35. Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK (2006) Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 15:177–206

    Article  PubMed  Google Scholar 

  36. Correll CU, Sheridan EM, DelBello MP (2010) Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord 12:116–141

    Article  PubMed  CAS  Google Scholar 

  37. Crocq MA, Guillon MS, Bailey PE, Provost D (2007) Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 22:453–454

    Article  PubMed  Google Scholar 

  38. Cui YH, Zheng Y, Yang YP, Liu J, Li J (2010) Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette’s disorder: a pilot study in China. J Child Adolesc Psychopharmacol 20:291–298

    Article  PubMed  Google Scholar 

  39. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT (2004) Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 14:372–394

    Article  PubMed  Google Scholar 

  40. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26:144–158

    Article  PubMed  Google Scholar 

  41. de Hoogd S, Overbeek WA, Heerdink ER, Correll CU, de Graeff ER, Staal WG (2012) Differences in body mass index z-scores and weight status in a Dutch pediatric psychiatric population with and without use of second-generation antipsychotics. J Child Adolesc Psychopharmacol 22:166–173

    Article  PubMed  CAS  Google Scholar 

  42. Degrauw RS, Li JZ, Gilbert DL (2009) Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. Pediatr Neurol 41:183–186

    Article  PubMed  Google Scholar 

  43. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM (2007) A 12-week single-blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 68:789–795

    Article  PubMed  CAS  Google Scholar 

  44. DelBello MP, Chang K, Welge JA, Adler CM, Rana M, Howe M, Bryan H, Vogel D, Sampang S, Delgado SV, Sorter M, Strakowski SM (2009) A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 11:483–493

    Article  PubMed  CAS  Google Scholar 

  45. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM (2006) A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 45:305–313

    Article  PubMed  Google Scholar 

  46. DelBello MP, Versavel M, Ice K, Keller D, Miceli J (2008) Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. J Child Adolesc Psychopharmacol 18:491–499

    Article  PubMed  Google Scholar 

  47. Dittmann RW, Meyer E, Freisleder FJ, Remschmidt H, Mehler-Wex C, Junghanss J, Hagenah U, Schulte-Markwort M, Poustka F, Schmidt MH, Schulz E, Mastele A, Wehmeier PM (2008) Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 18:54–69

    Article  PubMed  Google Scholar 

  48. Doey T (2012) Aripiprazole in pediatric psychosis and bipolar disorder: a clinical review. J Affect Disord 138(Suppl):S15–S21

    Article  PubMed  CAS  Google Scholar 

  49. Dori N, Green T (2011) The metabolic syndrome and antipsychotics in children and adolescents. Harefuah 150:791–796, 814, 813

    Google Scholar 

  50. Eapen V, John G (2011) Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go? Australas Psychiatry 19:232–235

    Article  PubMed  Google Scholar 

  51. Edlinger M, Hofer A, Rettenbacher MA, Baumgartner S, Widschwendter CG, Kemmler G, Neco NA, Fleischhacker WW (2009) Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. Schizophr Res 113:246–251

    Article  PubMed  Google Scholar 

  52. Fedorowicz VJ, Fombonne E (2005) Metabolic side effects of atypical antipsychotics in children: a literature review. J Psychopharmacol 19:533–550

    Article  PubMed  CAS  Google Scholar 

  53. Findling RL (2008) Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69(Suppl 4):9–14

    PubMed  CAS  Google Scholar 

  54. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B (2004) Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 161:677–684

    Article  PubMed  Google Scholar 

  55. Findling RL, Cavus I, Pappadolulos E, Backinsky M, Schwartz JH, Vanderburg DG (2010) A placebo-controlled trial to evaluate the efficacy and safety of flexibly dosed oral ziprasidone in adolescent subjects with schizophrenia. Schizophr Res 117:437

    Article  Google Scholar 

  56. Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, Lieberman JA, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L (2010) Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49:583–594 (quiz 632)

    PubMed  Google Scholar 

  57. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL (2000) A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 39:509–516

    Article  PubMed  CAS  Google Scholar 

  58. Findling RL, McNamara NK, Youngstrom EA, Stansbrey RJ, Frazier TW, Lingler J, Otto BD, Demeter CA, Rowles BM, Calabrese JR (2011) An open-label study of aripiprazole in children with a bipolar disorder. J Child Adolesc Psychopharmacol 21:345–351

    Article  PubMed  CAS  Google Scholar 

  59. Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K (2009) Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 70:1441–1451

    Article  PubMed  CAS  Google Scholar 

  60. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165:1432–1441

    Article  PubMed  Google Scholar 

  61. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A (2006) Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 16:308–316

    Article  PubMed  Google Scholar 

  62. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A (2007) Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. J Neural Transm 114:273–280

    Article  PubMed  CAS  Google Scholar 

  63. Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A (2008) Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 115:1599–1608

    Article  PubMed  CAS  Google Scholar 

  64. Fraguas D, Correll CU, Merchan-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C (2011) Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol 21:621–645

    Article  PubMed  CAS  Google Scholar 

  65. Fraguas D, Merchan-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giraldez M, Arango C (2008) Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69:1166–1175

    Article  PubMed  CAS  Google Scholar 

  66. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, Rater MA, Tarazi RA, Kim GS, Garfield SB, Sohma M, Gonzalez-Heydrich J, Risser RC, Nowlin ZM (2001) A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol 11:239–250

    Article  PubMed  CAS  Google Scholar 

  67. Frazier JA, Meyer MC, Biederman J, Wozniak J, Wilens TE, Spencer TJ, Kim GS, Shapiro S (1999) Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry 38:960–965

    Article  PubMed  CAS  Google Scholar 

  68. Frémaux T, Reymann JM, Chevreuil C, Bentue-Ferrer D (2007) Prescription of olanzapine in children and adolescent psychiatric patients. Encephale 33:188–196

    Article  PubMed  Google Scholar 

  69. Gagliano A, Germano E, Pustorino G, Impallomeni C, D’Arrigo C, Calamoneri F, Spina E (2004) Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol 14:39–47

    Article  PubMed  Google Scholar 

  70. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620–626

    Article  PubMed  Google Scholar 

  71. Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, Kuhnau W, Schmidtke J, Remschmidt H, Hebebrand J (2010) Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 35:207–211

    Article  PubMed  CAS  Google Scholar 

  72. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, Axelson DA, Bolhofner K, Robb A, Wolf DV, Riddle MA, Birmaher B, Nusrat N, Ryan ND, Vitiello B, Tillman R, Lavori P (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 69:515–528

    Article  PubMed  CAS  Google Scholar 

  73. Gencer O, Emiroglu FN, Miral S, Baykara B, Baykara A, Dirik E (2008) Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. Eur Child Adolesc Psychiatry 17:217–225

    Article  PubMed  Google Scholar 

  74. Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R (2010) Metabolic side effects of risperidone in early onset schizophrenia. Encephale 36:242–252

    Article  PubMed  Google Scholar 

  75. Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB (2008) Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry 69:1953–1959

    Article  PubMed  Google Scholar 

  76. Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, Weizman A, Apter A (2002) Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159:1055–1057

    Article  PubMed  Google Scholar 

  77. Green SB, Byar DP (1984) Using observational data from registries to compare treatments: the fallacy of omnimetrics. Stat Med 3:361–373

    Article  PubMed  CAS  Google Scholar 

  78. Gurpegui M, Martinez-Ortega JM, Gutierrez-Rojas L, Rivero J, Rojas C, Jurado D (2012) Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample. Prog Neuropsychopharmacol Biol Psychiatry 37:169–175

    Article  PubMed  Google Scholar 

  79. Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V (2009) Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 11:687–700

    Article  PubMed  CAS  Google Scholar 

  80. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V (2009) Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. Br J Psychiatry 194:158–164

    Article  PubMed  Google Scholar 

  81. Haas M, Karcher K, Pandina GJ (2008) Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol 18:337–345

    Article  PubMed  Google Scholar 

  82. Handen BL, Hardan AY (2006) Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. J Am Acad Child Adolesc Psychiatry 45:928–935

    Article  PubMed  Google Scholar 

  83. Hoekstra PJ, Troost PW, Lahuis BE, Mulder H, Mulder EJ, Franke B, Buitelaar JK, Anderson GM, Scahill L, Minderaa RB (2010) Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. J Child Adolesc Psychopharmacol 20:473–477

    Article  PubMed  Google Scholar 

  84. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, Novotny S (2006) A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16:541–548

    Article  PubMed  Google Scholar 

  85. Hrdlicka M, Zedkova I, Blatny M, Urbanek T (2009) Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuro Endocrinol Lett 30:256–261

    PubMed  CAS  Google Scholar 

  86. Jassim G, Ferno J, Theisen FM, Haberhausen M, Christoforou A, Havik B, Gebhardt S, Remschmidt H, Mehler-Wex C, Hebebrand J, Lehellard S, Steen VM (2011) Association study of energy homeostasis genes and antipsychotic-induced weight gain in patients with schizophrenia. Pharmacopsychiatry 44:15–20

    Article  PubMed  CAS  Google Scholar 

  87. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, Wozniak J, Lee SS, Schulz SC (2008) A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. J Child Adolesc Psychopharmacol 18:317–326

    Article  PubMed  Google Scholar 

  88. Jerrell JM, McIntyre RS (2008) Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 23:283–290

    Article  PubMed  Google Scholar 

  89. Jolin EM, Weller EB, Weller RA (2007) The public health aspects of bipolar disorder in children and adolescents. Curr Psychiatry Rep 9:106–113

    Article  PubMed  Google Scholar 

  90. Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J (2012) A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord 136:1143–1153

    Article  PubMed  CAS  Google Scholar 

  91. Kapetanovic S, Aaron L, Montepiedra G, Sirois PA, Oleske JM, Malee K, Pearson DA, Nichols SL, Garvie PA, Farley J, Nozyce ML, Mintz M, Williams PL (2009) The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV. AIDS Patient Care STDS 23:939–947

    Article  PubMed  Google Scholar 

  92. Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R (2009) A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res 113:41–48

    Article  PubMed  CAS  Google Scholar 

  93. Kelly DL, Conley RR, Love RC, Horn DS, Ushchak CM (1998) Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 8:151–159

    Article  PubMed  CAS  Google Scholar 

  94. Kemner C, Willemsen-Swinkels SH, de Jonge M, Tuynman-Qua H, van Engeland H (2002) Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22:455–460

    Article  PubMed  CAS  Google Scholar 

  95. Khan RA, Mican LM, Suehs BT (2009) Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation. J Psychiatr Pract 15:320–328

    Article  PubMed  Google Scholar 

  96. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA (2006) A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 163:2072–2079

    Article  PubMed  Google Scholar 

  97. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, Bauer T, Xu W, Wang W, Carlson J, Tohen M (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48:60–70

    Article  PubMed  Google Scholar 

  98. Kryzhanovskaya LA, Robertson-Plouch CK, Xu W, Carlson JL, Merida KM, Dittmann RW (2009) The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials. J Clin Psychiatry 70:247–258

    Article  PubMed  CAS  Google Scholar 

  99. Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O (2012) Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine. J Child Adolesc Psychopharmacol 22:157–165

    Article  PubMed  CAS  Google Scholar 

  100. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM (2008) Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63:524–529

    Article  PubMed  Google Scholar 

  101. Lindsay RL, Leone S, Aman MG (2004) Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr (Phila) 43:437–444

    Article  Google Scholar 

  102. Luby J, Mrakotsky C, Stalets MM, Belden A, Heffelfinger A, Williams M, Spitznagel E (2006) Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16:575–587

    Article  PubMed  Google Scholar 

  103. Maayan L, Correll CU (2011) Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 21:517–535

    Article  PubMed  CAS  Google Scholar 

  104. Malhotra AK, Correll CU, Chowdhury NI, Muller DJ, Gregersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, Meltzer HY, Lencz T, Kennedy JL (2012) Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry 69:904–912

    Article  PubMed  CAS  Google Scholar 

  105. Marcus RN, Owen R, Manos G, Mankoski R, Kamen L, McQuade RD, Carson WH, Findling RL (2011) Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study. J Clin Psychiatry 72:1270–1276

    Article  PubMed  CAS  Google Scholar 

  106. Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99–107

    Article  PubMed  CAS  Google Scholar 

  107. Martin A, L’Ecuyer S (2002) Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry 11:129–133

    Article  PubMed  CAS  Google Scholar 

  108. Martin A, Landau J, Leebens P, Ulizio K, Cicchetti D, Scahill L, Leckman JF (2000) Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 10:259–268

    Article  PubMed  CAS  Google Scholar 

  109. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (2004) Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161:1125–1127

    Article  PubMed  Google Scholar 

  110. Martinez-Ortega JM, Diaz-Atienza F, Gutierrez-Rojas L, Jurado D, Gurpegui M (2011) Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents. Eur Child Adolesc Psychiatry 20:597–598

    Article  PubMed  Google Scholar 

  111. Masi G, Cosenza A, Mucci M, Brovedani P (2001) Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 40:1206–1214

    Article  PubMed  CAS  Google Scholar 

  112. Masi G, Milone A, Canepa G, Millepiedi S, Mucci M, Muratori F (2006) Olanzapine treatment in adolescents with severe conduct disorder. Eur Psychiatry 21:51–57

    Article  PubMed  Google Scholar 

  113. Masi G, Mucci M, Millepiedi S (2002) Clozapine in adolescent inpatients with acute mania. J Child Adolesc Psychopharmacol 12:93–99

    Article  PubMed  Google Scholar 

  114. McConville B, Carrero L, Sweitzer D, Potter L, Chaney R, Foster K, Sorter M, Friedman L, Browne K (2003) Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. J Child Adolesc Psychopharmacol 13:75–82

    Article  PubMed  Google Scholar 

  115. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321

    Article  PubMed  CAS  Google Scholar 

  116. McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J (2008) Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol 18:501–508

    Article  PubMed  Google Scholar 

  117. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ (1997) Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry 36:685–693

    Article  PubMed  CAS  Google Scholar 

  118. McIntyre RS, Jerrell JM (2008) Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents. Arch Pediatr Adolesc Med 162:929–935

    Article  PubMed  Google Scholar 

  119. Moreno C, Merchan-Naranjo J, Alvarez M, Baeza I, Alda JA, Martinez-Cantarero C, Parellada M, Sanchez B, de la Serna E, Giraldez M, Arango C (2010) Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses. Bipolar Disord 12:172–184

    Article  PubMed  Google Scholar 

  120. Mozes T, Ebert T, Michal SE, Spivak B, Weizman A (2006) An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 16:393–403

    Article  PubMed  Google Scholar 

  121. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R (2003) Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 13:311–317

    Article  PubMed  Google Scholar 

  122. Mukaddes NM, Abali O, Gurkan K (2004) Short-term efficacy and safety of risperidone in young children with autistic disorder (AD). World J Biol Psychiatry 5:211–214

    Article  PubMed  Google Scholar 

  123. Nagaraj R, Singhi P, Malhi P (2006) Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21:450–455

    PubMed  Google Scholar 

  124. Nicolson R, Awad G, Sloman L (1998) An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 37:372–376

    Article  PubMed  CAS  Google Scholar 

  125. Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540

    Article  PubMed  Google Scholar 

  126. Panagiotopoulos C, Ronsley R, Davidson J (2009) Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications. Can J Psychiatry 54:743–749

    PubMed  Google Scholar 

  127. Patel NC, Hariparsad M, Matias-Akthar M, Sorter MT, Barzman DH, Morrison JA, Stanford KE, Strakowski SM, DelBello MP (2007) Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol 17:303–311

    Article  PubMed  Google Scholar 

  128. Patel NC, Kistler JS, James EB, Crismon ML (2004) A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents. Pharmacotherapy 24:824–830

    Article  PubMed  CAS  Google Scholar 

  129. Pringsheim T, Lam D, Ching H, Patten S (2011) Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Saf 34:651–668

    Article  PubMed  Google Scholar 

  130. Pulkki-Raback L, Elovainio M, Kivimaki M, Mattsson N, Raitakari OT, Puttonen S, Marniemi J, Viikari JS, Keltikangas-Jarvinen L (2009) Depressive symptoms and the metabolic syndrome in childhood and adulthood: a prospective cohort study. Health Psychol 28:108–116

    Article  PubMed  Google Scholar 

  131. Quintana H, Wilson MS 2nd, Purnell W, Layman AK, Mercante D (2007) An open-label study of olanzapine in children and adolescents with schizophrenia. J Psychiatr Pract 13:86–96

    Article  PubMed  Google Scholar 

  132. Ratzoni G, Gothelf D, Brand-Gothelf A, Reidman J, Kikinzon L, Gal G, Phillip M, Apter A, Weizman R (2002) Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 41:337–343

    Article  PubMed  Google Scholar 

  133. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M (2006) Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 15:97–104

    Article  PubMed  Google Scholar 

  134. Reynolds GP, Zhang ZJ, Zhang XB (2002) Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 359:2086–2087

    Article  PubMed  CAS  Google Scholar 

  135. Robb AS, Andersson C, Bellocchio EE, Manos G, Rojas-Fernandez C, Mathew S, Marcus R, Owen R, Mankoski R (2011) Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6-17 years old): results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord 13

  136. Ross RG, Novins D, Farley GK, Adler LE (2003) A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 13:301–309

    Article  PubMed  Google Scholar 

  137. Safer DJ (2004) A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24:429–436

    Article  PubMed  CAS  Google Scholar 

  138. Saklad SR, Ketchi CM, Amrung SA (2002) Gender differences in weight gain among adolescents started on atypical antipsychotics. J Child Adolesc Psychopharmacol 12:288–289

    Article  Google Scholar 

  139. Sallee FR, Kurlan R, Goetz CG, Singer H, Scahill L, Law G, Dittman VM, Chappell PB (2000) Ziprasidone treatment of children and adolescents with Tourette’s syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 39:292–299

    Article  PubMed  CAS  Google Scholar 

  140. Schimmelmann BG, Mehler-Wex C, Lambert M, Schulze-zur-Wiesch C, Koch E, Flechtner HH, Gierow B, Maier J, Meyer E, Schulte-Markwort M (2007) A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders. J Child Adolesc Psychopharmacol 17:768–778

    Article  PubMed  Google Scholar 

  141. Shaw JA, Lewis JE, Pascal S, Sharma RK, Rodriguez RA, Guillen R, Pupo-Guillen M (2001) A study of quetiapine: efficacy and tolerability in psychotic adolescents. J Child Adolesc Psychopharmacol 11:415–424

    Article  PubMed  CAS  Google Scholar 

  142. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL (2006) Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 63:721–730

    Article  PubMed  CAS  Google Scholar 

  143. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634–e641

    Article  PubMed  Google Scholar 

  144. Sholevar EH, Baron DA, Hardie TL (2000) Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol 10:69–78

    Article  PubMed  CAS  Google Scholar 

  145. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420–1431

    Article  PubMed  Google Scholar 

  146. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA (2004) A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29:133–145

    Article  PubMed  CAS  Google Scholar 

  147. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A (2002) Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026–1036

    Article  PubMed  Google Scholar 

  148. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM (2010) A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int Clin Psychopharmacol 25:1–6

    Article  PubMed  Google Scholar 

  149. Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL (1999) Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 9:93–98

    Article  PubMed  CAS  Google Scholar 

  150. Theisen FM, Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, Kuhnau W, Schmidtke J, Remschmidt H, Hebebrand J (2005) Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 15:285–289

    Article  PubMed  Google Scholar 

  151. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA (2009) Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 70:756–764

    Article  PubMed  CAS  Google Scholar 

  152. Turgay A, Binder C, Snyder R, Fisman S (2002) Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 110:e34

    Article  PubMed  Google Scholar 

  153. Van Bellinghen M, De Troch C (2001) Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 11:5–13

    Article  PubMed  Google Scholar 

  154. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J (2009) Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol 19:539–545

    Article  PubMed  Google Scholar 

  155. Zuddas A, Di Martino A, Muglia P, Cianchetti C (2000) Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation. J Child Adolesc Psychopharmacol 10:79–90

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors report no biomedical financial interests or potential conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Faculty of Medicine, University of Granada, Av. Madrid 11, 18071, Granada, Spain

    José María Martínez-Ortega, Francisco Díaz-Atienza & Manuel Gurpegui

  2. Child and Adolescent Mental Health Unit, Virgen de las Nieves University Hospital, Granada, Spain

    José María Martínez-Ortega, Silvia Funes-Godoy & Francisco Díaz-Atienza

  3. CTS-549 Research Group, Institute of Neurosciences, Centre for Biomedical Research (CIBM), University of Granada, Granada, Spain

    José María Martínez-Ortega, Francisco Díaz-Atienza, Luis Gutiérrez-Rojas & Manuel Gurpegui

  4. Psychiatry Service, San Cecilio University Hospital, Granada, Spain

    Luis Gutiérrez-Rojas

  5. Psychiatry Service, Carlos Haya University Hospital, Málaga, Spain

    Lucía Pérez-Costillas

  6. Department of Psychiatry, University of Málaga, Málaga, Spain

    Lucía Pérez-Costillas

Authors
  1. José María Martínez-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvia Funes-Godoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francisco Díaz-Atienza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luis Gutiérrez-Rojas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lucía Pérez-Costillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Manuel Gurpegui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José María Martínez-Ortega.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martínez-Ortega, J.M., Funes-Godoy, S., Díaz-Atienza, F. et al. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry 22, 457–479 (2013). https://doi.org/10.1007/s00787-013-0399-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00787-013-0399-5

Keywords

Search

Navigation